Stockholm, April 7, 2011 — NASDAQ OMX (NASDAQ: NDAQ) announces that trading in Pledpharma AB (short name: PLED) shares will commence today, April 7, on First North at NASDAQ OMX Stockholm. Pledpharma belongs to the Health Care sector.
Pledpharma develops therapies for severe diseases. By streamlining the different treatments the company's drugs are designed to reduce serious side effects while increasing patient survival rates. Pledpharma currently has two projects in clinical Phase II, one in the cancer field and one in the cardiovascular field. For more information see www.pledpharma.se.
Jenny Rosberg, Senior Vice President at NASDAQ OMX said, “We are pleased that Pledpharma chose to list at First North, one of Europe’s most liquid growth markets, where they will make a great addition to our healthcare sector. We continue to see a steady listing inflow to First North and welcome more companies to take advantage of the investor visibility and reach that we can offer.”
Pledpharma’s CEO, Jacques Näsström, commented, “Today marks an exciting day for our company and we look forward to benefiting from the increased investor exposure at First North. Pledpharma operates in a market with tremendous potential, and on First North we are able to build the capital strength needed to support continued and organic growth.”
Pledpharma has appointed Erik Penser Aktiebolag as Certified Advisor.
Cautionary Note Regarding Forward-Looking Statements
The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about NASDAQ OMX's products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond NASDAQ OMX's control. These factors include, but are not limited to factors detailed in NASDAQ OMX's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.
NASDAQ OMX Media contact:
Carl Norell +46 8 405 6639